Abstract

Neutralizing Soluble TNF to Overcome Resistance to Immunotherapy

RJ Tesi, CEO/CMO, Inmune Bio Inc

The complexity of TNF biology is not understood by scientists, biopharma or clinicians.  In cancer, soluble TNF promotes tumor growth, EMT and metastasis.  In the TME, sTNF directly or indirectly recruits MDSC, TAM and Tregs while decreasing the TIL infiltration.  The result is a tumor that grows, is resistant to therapy and prone to metastasis.  Neutralizing sTNF reverses these immunologic resistance factors to allow the patient’s immune system and immunotherapy to better control the tumor.  The therapy must be targeted, selective inhibitor of only sTNF.  Currently approved non-selective TNF inhibitors should not be used because they inhibit trans-membrane TNF to promote immunosuppression.  Pre-clinical and clinical data will be presented.